{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:41:43Z","timestamp":1785440503003,"version":"3.56.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903711, 81970698, 81970708"],"award-info":[{"award-number":["81903711, 81970698, 81970708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Glucokinase activators (GKAs) promote the activity of glucokinase (GK) and is under development for the treatment of diabetes. The efficacy and safety of GKAs require evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This meta-analysis included randomized controlled trials (RCTs) with a duration of at least 12 weeks conducted in patients with diabetes. The primary objective of this meta-analysis was the difference of hemoglobin A1c (HbA1c) change from baseline to study end between GKA groups and placebo groups. Risk of hypoglycemia and laboratory indicators were also evaluated. Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for the continuous outcomes, and odds ratios (ORs) and 95% CI were calculated for the risk of hypoglycemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 13 RCTs with 2,748 participants treated with GKAs and 2,681 control participants were analyzed. In type 2 diabetes, the level of HbA1c decreased greater in patients with GKA treatment compared with placebo (WMD = -0.339%, 95% CI -0.524 to -0.154%, P &amp;lt; 0.001). The OR comparing GKA versus placebo was 1.448 for risk of hypoglycemia (95% CI 0.808 to 2.596, P = 0.214). The WMD comparing GKA versus placebo was 0.322 mmol\/L for triglyceride (TG) levels (95% CI 0.136 to 0.508 mmol\/L, P = 0.001). When stratified by drug type, selectivity, and study duration, a significant difference was found between groups. In type 1 diabetes, the result of HbA1c change and lipid indicators showed no significant difference between the TPP399 group and the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with type 2 diabetes, GKA treatment was associated with a better glycemic control but a significant elevation in TG concentration in general. The efficacy and safety varied with drug type and selectivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>International Prospective Register of Systematic Reviews, identifier CRD42022378342.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1175198","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:47:52Z","timestamp":1683521272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of efficacy and safety of glucokinase activators\u2014a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Wenjia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"B1","volume-title":"IDF diabetes atlas","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2049","article-title":"Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes","volume":"95","author":"Perseghin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of hepatic glucose metabolism in health and disease","volume":"13","author":"Petersen","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B4","unstructured":"Approval of dorzagliatin by the national medical products administration"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01278-z","article-title":"Glucokinase activators for type 2 diabetes: challenges and future developments","volume":"80","author":"Toulis","year":"2020","journal-title":"Drugs."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30196-7","article-title":"Non-alcoholic fatty liver disease concerns with glucokinase activators","volume":"6","author":"Hodson","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1200","article-title":"Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes","volume":"34","author":"Meininger","year":"2011","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12088","article-title":"Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin","volume":"15","author":"Wilding","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12100","article-title":"Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Kiyosue","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01802-6","article-title":"Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01803-5","article-title":"Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Yang","year":"2022","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane bias methods group cochrane statistical methods group. the cochrane collaboration's tool for assessing risk of bias in randomized trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau3441","article-title":"Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator","volume":"11","author":"Vella","year":"2019","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12294","article-title":"Present status of clinical deployment of glucokinase activators","volume":"6","author":"Nakamura","year":"2015","journal-title":"J Diabetes Investig"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.11.007","article-title":"GKAs for diabetes therapy: why no clinically useful drug after two decades of trying","volume":"34","author":"Matschinsky","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.965680","article-title":"Lessons from glucokinase activators: the problem of declining efficacy","volume":"24","author":"Agius","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2017","article-title":"Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans","volume":"96","author":"Peter","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.08.004","article-title":"Modulation of glucokinase regulatory protein: a double-edged sword","volume":"21","author":"Brouwers","year":"2015","journal-title":"Trends Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-012-1151-9","article-title":"Association between gout and polymorphisms in GCKR in male han Chinese","volume":"131","author":"Wang","year":"2012","journal-title":"Hum Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206191","article-title":"Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes","volume":"75","author":"Matsuo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp489","article-title":"Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms","volume":"19","author":"van der Harst","year":"2009","journal-title":"Hum Mol Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000504","article-title":"Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations","volume":"5","author":"Kolz","year":"2009","journal-title":"PloS Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2016.08.002","article-title":"In type 1 diabetics, high-dose biotin may compensate for low hepatic insulin exposure, promoting a more normal expression of glycolytic and gluconeogenic enyzymes and thereby aiding glycemic control","volume":"95","author":"McCarty","year":"2016","journal-title":"Med Hypotheses"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/10430340260201653","article-title":"Adenovirusmediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes","volume":"13","author":"Morral","year":"2002","journal-title":"Hum Gene Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2684","article-title":"The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b\/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes","volume":"44","author":"Klein","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1175198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:47:58Z","timestamp":1683521278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1175198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":28,"alternative-id":["10.3389\/fendo.2023.1175198"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1175198","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"article-number":"1175198"}}